For more information contact us today!
Work was done in collaboration with MDxHealth.
13 Jan 2021 | Client cases
By Kathryn Morrissey for BioLizard
MDxHealth is a front runner in epigenetic research with a proven track record of identifying, developing, validating and delivering molecular diagnostic assays. They provide functional genomic data that can be used for personalised cancer risk assessment, with specific focus on prostate cancer.
Assisted with development and optimisation of a robust model to calculate patient
risk score for prostate cancer based on clinical biomarkers and other clinical features.
Optimise current qualification of reagents/equipment. Instead of head-to-head
approach, develop a QC panel that can be used in each run to see if they fall in
between the expected QC ranges.
“We were very pleased with the work BioLizard did. The BioLizard team were very flexible and took the necessary time to fully understand our needs. Their tailored service allowed us to draw meaningful conclusions from our data.” – MDxHealth